Prescribe Right
Prescribe Right
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
  • Home
  • About
    • Endorsements
    • Published Articles
    • Consulting
    • Effective Pharmacotherapy
  • Pipeline News
    • Podcast
    • Recent Tweets
  • Pharmaceutical Pipeline Tracker
    • Access Pharmaceutical Pipeline Tracker
    • Pharmaceutical Pipeline Tracker Demo
    • Sample Drug Review
    • Case Studies >
      • Monitoring Drugs With PDUFA Dates
      • Monitoring Drugs By Therapeutic Category
      • Monitoring by Indication
      • Research a Single Drug
    • Sample Searches >
      • Single Drug Report Sample
      • Indication Search Sample
      • Drug Class Search Sample
      • Therapeutic Area Search Sample
      • Company Search Sample
  • COVID-19
    • COVID-19 Updates
    • COVID-19 Vaccines
    • COVID-19 Antivirals
    • COVID-19 Monoclonal Antibodies
    • COVID-19 Plasma Products
    • COVID-19 Anti-Inflammatories
    • Remdesivir
    • Ivermectin
  • Contact Us
Pipeline News and Updates
Picture

Update for June 17, 2020

6/16/2020

 
Regulatory Update
 
The FDA approved inebilizumab-cdon (Uplizna, Viela Bio) on 6/11/2020 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. 
 
The FDA designated Insmed’s brensocatib a Breakthrough Therapy for the treatment of non-cystic fibrosis bronchiectasis.
 
Leo Pharma announced the EU accepted the MAA for AstraZeneca/Leo Pharma’s tralokinumab as a treatment for moderate-to-severe atopic dermatitis.
 
Announced Research Updates
 
AbbVie announced that in the 12-week, 612 patient, Phase III, SELECT-CHOICE trial, patients treated with upadacitinib had a 2.52 reduction in their DAS28CRP score compared to a 2 point reduction with abatacept in patients with rheumatoid arthritis previously treated with a biologic.
 
GSK announced interim data from 18 patients enrolled in the Phase I/II, open-label, DREAMM-6 trial, where treatment with belantamab mafodotin plus bortezomib and dexamethasone resulted in an overall response rate of 78% in patients with relapsed/refractory multiple myeloma.
 
Pfizer announced that in a 12-week, 387 patient, Phase III, JADE MONO-TEEN trial, more patients treated with abrocitinib 200 mg achieved an IGA score of clear or almost clear skin and had a 2 point or > improvement in their IGA score compared to placebo in patients 12 to < 18 years of age with moderate to severe atopic dermatitis (AD) who were also on background topical therapy. Treatment with the 200 mg dose also resulted in more patients achieving at least a 75% or greater improvement in their Eczema Area and Severity Index (EASI) score compared to placebo. The 100 mg dose did not differ from placebo for IGA or EASI scores.
 
Opthea announced that in a 12-week, 155 patient Phase IIa trial, treatment with OPT-302 plus aflibercept did not improve the number of patients that achieved a 5 letter or > gain in Best Corrected Visual Acuity compared to aflibercept monotherapy (52% vs 60%) in patients with persistent diabetic macula edema despite regular intravitreal administration of prior anti-VEGF-A monotherapy.
 
Bluebird announced 6-month interim results for 16 patients enrolled in the Phase I/II, HGB-206 trial, where treatment with beta beglogene darolentivec resulted in total hemoglobin from 9.6 to 16.2 g/dL, HbAT87Q levels from 2.7 to 9.4 g/dL and a 99.5% mean reduction in annualized rate of vaso-occlusive crises and acute chest syndrome in patients with sickle cell disease.
 
ADC announced that in the 145 patient, Phase II, open-label, LOTIS 2 trial, treatment with loncastuximab tesirine resulted in an ORR of 48.3% and a complete response rate (CRR) of 24.1% in patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL). ADC announced interim results from 18 patients enrolled in the Phase I/II, open-label, LOTIS 3 trial, where treatment with loncastuximab tesirine plus ibrutinib resulted in an ORR of 66.7% and a CRR of 33% in patients with relapsed or refractory DLBCL or mantle cell lymphoma (MCL).
 
Published Research Updates
 
In the 12-month, 81 patient, Phase II, open-label, L-MIND trial, treatment with tafasitamab plus lenalidomide resulted in an overall response rate of 60% in patients with diffuse large B cell lymphoma. In a 92 patient, Phase II, open-label trial, treatment with tafasitamab resulted in an overall response rate of 26% in diffuse large B cell lymphoma patients, 29% in follicular lymphoma patients and 27% in indolent non-Hodgkin's lymphoma patients.


Comments are closed.
    Stay informed, subscribe to the 
    ​
    Prescribe Right Pharmaceutical Pipeline Tracker
    Latest Tweets from Prescribe Right

    Archives

    January 2023
    December 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    January 2022
    December 2021
    November 2021
    October 2021
    September 2021
    August 2021
    July 2021
    June 2021
    May 2021
    April 2021
    March 2021
    February 2021
    January 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    July 2020
    June 2020
    May 2020
    April 2020
    March 2020
    February 2020
    January 2020
    December 2019
    November 2019
    October 2019
    September 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    August 2015

    RSS Feed

Services

Pharmaceutical Pipeline Tracker​
Consulting

Company

About
Blog
Tweets

Support

Contact
© COPYRIGHT 2015. ALL RIGHTS RESERVED.